Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 376Polycystic Ovary Syndrome 41Neoplasm Metastasis 23Endometrial Neoplasms 22Ovarian Neoplasms 16Neoplasms 14Infertility 12Advanced Breast Cancer 10Fallopian Tube Neoplasms 8Carcinoma, Intraductal, Noninfiltrating 8Triple Negative Breast Neoplasms 7Recurrence 7Osteoporosis 7Carcinoma, Ductal, Breast 7Breast Neoplasms, Male 7Breast Diseases 7Carcinoma, Lobular 6Breast Carcinoma In Situ 6Prostatic Neoplasms 5Leiomyoma 4Infertility, Female 4Hereditary Sensory and Autonomic Neuropathies 4Breast Cancer Metastatic 4Arthralgia 4Obesity 3Neoplasms, Hormone-Dependent 3Carcinoma, Ovarian Epithelial 3Carcinoma, Non-Small-Cell Lung 3Anovulation 3Uterine Neoplasms 2

Interventions

Letrozole 1Goserelin 1Erlotinib Hydrochloride 13-(8-amino-1-(2-phenylquinolin-7-yl)imidazo(1,5-a)pyrazin-3-yl)-1-methylcyclobutanol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hormone-sensitive Metastatic Breast Cancer × Letrozole × Clear all
NCT01205685 2012-09-11

Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-Sensitive Metastatic Breast Cancer

Vanderbilt-Ingram Cancer Center

Phase 2 Terminated
11 enrolled 9 charts
Breast

Hormone-sensitive Metastatic Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡